Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
PKI > SEC Filings for PKI > Form 10-Q on 5-Nov-2013All Recent SEC Filings

Show all filings for PERKINELMER INC

Form 10-Q for PERKINELMER INC


5-Nov-2013

Quarterly Report


Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations

This quarterly report on Form 10-Q, including the following management's discussion and analysis, contains forward-looking information that you should read in conjunction with the condensed consolidated financial statements and notes to the condensed consolidated financial statements that we have included elsewhere in this report. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "plans," "anticipates," "intends," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our actual results may differ materially from the plans, intentions or expectations we disclose in the forward-looking statements we make. We have included important factors below under the heading "Risk Factors" in Part II, Item 1A. that we believe could cause actual results to differ materially from the forward-looking statements we make. We are not obligated to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Overview
We are a leading provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through our advanced technologies, solutions, and services, we address critical issues that help to improve the health and safety of people and their environment.
We realigned our organization at the beginning of fiscal year 2013. Our field service for products previously sold by our former Bio-discovery business, as well as our Informatics business, were moved from our Environmental Health segment into our Human Health segment. The results reported for the three and nine months ended September 29, 2013 reflect this new alignment of our operating segments. Financial information in this report relating to the three and nine months ended September 30, 2012 has been retrospectively adjusted to reflect the changes in our operating segments. The principal products and services of our two operating segments are:

         Human Health.  Develops diagnostics, tools and applications to help
          detect diseases earlier and more accurately and to accelerate the
          discovery and development of critical new therapies. The Human Health
          segment serves both the diagnostics and research markets.


         Environmental Health.  Provides technologies and applications to
          facilitate the creation of safer food and consumer products, more
          secure surroundings and efficient energy resources. The Environmental
          Health segment serves the environmental, industrial and laboratory
          services markets.

As a result of the realignment, we reallocated goodwill from the Environmental Health segment to the Human Health segment based on the relative fair value, determined using the income approach, of the businesses within the historical Environmental Health segment. The change resulted in $215.7 million of goodwill being allocated from the Environmental Health segment to the Human Health segment as of December 30, 2012.
Overview of the Third Quarter of Fiscal Year 2013 Our fiscal year ends on the Sunday nearest December 31. We report fiscal years under a 52/53 week format, and as a result certain fiscal years will contain 53 weeks. Both our 2013 and 2012 fiscal years include 52 weeks.
Our overall revenue in the third quarter of fiscal year 2013 was $524.3 million and increased $14.7 million, or 3%, as compared to the third quarter of fiscal year 2012, reflecting an increase of $5.1 million, or 2%, in our Human Health segment revenue and an increase of $9.5 million, or 4%, in our Environmental Health segment revenue. The increase in our Human Health segment revenue during the three months ended September 29, 2013 was due to growth generated from our informatics offerings and in-vivo business in the research market. The increase in our Environmental Health segment revenue during the three months ended September 29, 2013 was primarily due to an increase in our OneSource multivendor service offerings within our lab services market.
In our Human Health segment during the third quarter of fiscal year 2013 as compared to the third quarter of fiscal year 2012, we experienced growth in the research market as demand increased for our informatics offerings and our in-vivo imaging systems. In the diagnostics market we experienced growth from continued expansion of our prenatal, newborn and infectious disease screening solutions in key regions outside the United States, particularly in emerging markets such as China and the Middle East. This growth was offset by declines in our medical imaging business despite continued growth in our complementary metal-oxide-semiconductor imaging technology with two new industrial product offerings. As the rising cost of healthcare continues to be one of the critical issues facing our customers, we anticipate that the benefits of providing earlier detection of disease, which can result in savings of long-term health care costs as well as create better outcomes for patients, are increasingly valued and we expect to see continued growth in these markets.


Table of Contents

In our Environmental Health segment, our laboratory services business offers services designed to enable our customers to increase efficiencies and production time, while reducing maintenance costs, all of which continue to be critical for our customers. During the third quarter of fiscal year 2013, we continued to grow our laboratory services business by the addition of new customers to our OneSource multivendor service offering. In the third quarter of fiscal year 2013, as compared to the third quarter of fiscal year 2012, we had an increase in demand across most of our products in the environmental and safety and industrial markets. We anticipate that the continued development of contaminant regulations and corresponding testing protocols will result in increased demand for efficient, analytically sensitive and information rich testing solutions.
Our consolidated gross margins decreased 74 basis points in the third quarter of fiscal year 2013, as compared to the third quarter of fiscal year 2012, due to pricing pressure, unfavorable changes in product mix, with an increase in sales of lower gross margin product offerings, and inflation, which were partially offset by increased sales volume and cost containment and productivity initiatives. Our consolidated operating margins increased 243 basis points in the third quarter of fiscal year 2013, as compared to the third quarter of fiscal year 2012, primarily due to lower costs as a result of restructuring activities and cost containment and productivity initiatives, which were partially offset by lower gross margins.
We believe we are well positioned to continue to take advantage of the spending trends in our end markets and to promote our efficiencies in markets where current conditions may increase demand for certain services. Overall, we believe that our strategic focus on Human Health and Environmental Health coupled with our breadth of end markets, deep portfolio of technologies and applications, leading market positions, global scale and financial strength will provide us with a foundation for growth.

Critical Accounting Policies and Estimates The preparation of condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, sales and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, warranty costs, bad debts, inventories, accounting for business combinations and dispositions, long-lived assets, income taxes, restructuring, pensions and other postretirement benefits, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Critical accounting policies are those policies that affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements. We believe our critical accounting policies include our policies regarding revenue recognition, warranty costs, allowances for doubtful accounts, inventory valuation, business combinations, value of long-lived assets, including goodwill and other intangibles, employee compensation and benefits, restructuring activities, gains or losses on dispositions and income taxes.
For a more detailed discussion of our critical accounting policies and estimates, please refer to the Notes to our Audited Consolidated Financial Statements and Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations," in our Annual Report on Form 10-K for the fiscal year ended December 30, 2012 (our "2012 Form 10-K"), as filed with the Securities and Exchange Commission (the "SEC"). There have been no significant changes in our critical accounting policies and estimates during the nine months ended September 29, 2013.

Consolidated Results of Continuing Operations Revenue
Revenue for the three months ended September 29, 2013 was $524.3 million, as compared to $509.6 million for the three months ended September 30, 2012, an increase of $14.7 million, or 3%, which includes an approximate 0.2% decrease in revenue attributable to unfavorable changes in foreign exchange rates and an approximate 1% increase from acquisitions. The analysis in the remainder of this paragraph compares segment revenue for the three months ended September 29, 2013 as compared to the three months ended September 30, 2012 and includes the effect of foreign exchange rate fluctuations and acquisitions. Our Human Health segment revenue increased $5.1 million, or 2%, due to an increase in research market revenue of $6.2 million, partially offset by a decrease in diagnostics market revenue of $1.1 million. Our Environmental Health segment revenue increased $9.5 million, or 4%, due to an increase in laboratory services market revenue of $5.1 million and increases in environmental and safety and industrial markets revenue of $4.5 million. As a result of adjustments to deferred revenue related to certain acquisitions required by business combination rules, we did not recognize $0.9 million of revenue for the three months ended September 29, 2013 and $5.2 million for the three months ended September 30, 2012 that otherwise would have been recorded by the acquired businesses during each of the respective periods.


Table of Contents

Revenue for the nine months ended September 29, 2013 was $1,573.0 million, as compared to $1,542.3 million for the nine months ended September 30, 2012, an increase of $30.7 million, or 2%, which includes an approximate 0.5% decrease in revenue attributable to unfavorable changes in foreign exchange rates and an approximate 1% increase from acquisitions. The analysis in the remainder of this paragraph compares segment revenue for the nine months ended September 29, 2013 as compared to the nine months ended September 30, 2012 and includes the effect of foreign exchange rate fluctuations and acquisitions. Our Human Health segment revenue increased $17.9 million, or 2%, due to an increase in diagnostics market revenue of $9.3 million and an increase in research market revenue of $8.6 million. Our Environmental Health segment revenue increased $12.8 million, or 2%, due to an increase in laboratory services market revenue of $17.8 million, partially offset by decreases in environmental and safety and industrial markets revenue of $5.0 million. As a result of adjustments to deferred revenue related to certain acquisitions required by business combination rules, we did not recognize $6.6 million of revenue for the nine months ended September 29, 2013 and $22.2 million for the nine months ended September 30, 2012 that otherwise would have been recorded by the acquired businesses during each of the respective periods.
Cost of Revenue
Cost of revenue for the three months ended September 29, 2013 was $290.8 million, as compared to $278.9 million for the three months ended September 30, 2012, an increase of $11.9 million, or 4%. As a percentage of revenue, cost of revenue increased to 55.5% for the three months ended September 29, 2013, from 54.7% for the three months ended September 30, 2012, resulting in a decrease in gross margin of 74 basis points to 44.5% for the three months ended September 29, 2013, from 45.3% for the three months ended September 30, 2012. Amortization of intangible assets increased and was $14.2 million for the three months ended September 29, 2013, as compared to $12.7 million for the three months ended September 30, 2012. Stock-based compensation expense was $0.3 million for each of the three months ended September 29, 2013 and September 30, 2012. Acquisition related costs related to certain acquisitions were $0.2 million for the three months ended September 29, 2013. In addition to the above, the overall decrease in gross margin was primarily the result of pricing pressure and unfavorable changes in product mix with an increase in sales of lower gross margin product offerings, partially offset by cost containment and productivity improvements.
Cost of revenue for the nine months ended September 29, 2013 was $872.3 million, as compared to $840.7 million for the nine months ended September 30, 2012, an increase of $31.5 million, or 4%. As a percentage of revenue, cost of revenue increased to 55.5% for the nine months ended September 29, 2013, from 54.5% for the nine months ended September 30, 2012, resulting in a decrease in gross margin of 94 basis points to 44.5% for the nine months ended September 29, 2013, from 45.5% for the nine months ended September 30, 2012. Amortization of intangible assets increased and was $39.8 million for the nine months ended September 29, 2013, as compared to $38.7 million for the nine months ended September 30, 2012. Stock-based compensation expense was $1.0 million for the nine months ended September 29, 2013, as compared to $0.9 million for the nine months ended September 30, 2012. The amortization of purchase accounting adjustments to record the inventory from certain acquisitions and other acquisition costs was $0.4 million for the nine months ended September 29, 2013, as compared to $4.8 million for the nine months ended September 30, 2012. In addition to the above, the overall decrease in gross margin was primarily the result of pricing pressure and unfavorable changes in product mix with an increase in sales of lower gross margin product offerings, partially offset by productivity improvements.
Selling, General and Administrative Expenses Selling, general and administrative expenses for the three months ended September 29, 2013 were $143.6 million, as compared to $145.4 million for the three months ended September 30, 2012, a decrease of $1.8 million, or 1%. As a percentage of revenue, selling, general and administrative expenses decreased and were 27.4% for the three months ended September 29, 2013, as compared to 28.5% for the three months ended September 30, 2012. Amortization of intangible assets decreased and was $8.8 million for the three months ended September 29, 2013, as compared to $9.2 million for the three months ended September 30, 2012. Stock-based compensation expense decreased and was $3.2 million for the three months ended September 29, 2013, as compared to $4.6 million for the three months ended September 30, 2012. Acquisition related costs for contingent consideration and other acquisition costs related to certain acquisitions decreased and provided a benefit of $1.1 million for the three months ended September 29, 2013, as compared to a benefit of $1.8 million for the three months ended September 30, 2012. In addition to the above, the decrease in selling, general and administrative expenses was primarily the result of cost containment and productivity initiatives.
Selling, general and administrative expenses for the nine months ended September 29, 2013 were $443.9 million, as compared to $452.0 million for the nine months ended September 30, 2012, a decrease of $8.1 million, or 2%. As a percentage of revenue, selling, general and administrative expenses decreased and were 28.2% for the nine months ended September 29, 2013, as compared to 29.3% for the nine months ended September 30, 2012. Amortization of intangible assets decreased and was $27.8 million for the nine months ended September 29, 2013, as compared to $29.6 million for the nine months ended September 30, 2012. Stock-based compensation expense decreased and was $9.8 million for the nine months ended


Table of Contents

September 29, 2013, as compared to $13.9 million for the nine months ended September 30, 2012. Acquisition related costs for contingent consideration and other acquisition costs related to certain acquisitions increased and provided a benefit of $1.0 million for the nine months ended September 29, 2013, as compared to a benefit of $0.3 million for the nine months ended September 30, 2012. In addition to the above, the decrease in selling, general and administrative expenses was primarily the result of cost containment and productivity initiatives.
Research and Development Expenses
Research and development expenses for the three months ended September 29, 2013 were $31.5 million, as compared to $32.4 million for the three months ended September 30, 2012, a decrease of $0.9 million, or 3%. As a percentage of revenue, research and development expenses decreased and were 6.0% for the three months ended September 29, 2013, as compared to 6.4% for the three months ended September 30, 2012. Amortization of intangible assets was $0.1 million for each of the three months ended September 29, 2013 and September 30, 2012. Stock-based compensation expense was $0.2 million for each of the three months ended September 29, 2013 and September 30, 2012. Acquisition related costs related to certain acquisitions were $0.2 million for the three months ended September 29, 2013. We primarily directed research and development efforts during fiscal years 2013 and 2012 toward the diagnostics and research markets within our Human Health segment, and the environmental, and laboratory service and support markets within our Environmental Health segment, in order to help accelerate our growth initiatives.
Research and development expenses for the nine months ended September 29, 2013 were $100.3 million, as compared to $99.1 million for the nine months ended September 30, 2012, an increase of $1.2 million, or 1%. As a percentage of revenue, research and development expenses were 6.4% for each of the nine months ended September 29, 2013 and September 30, 2012. Amortization of intangible assets decreased and was $0.2 million for the nine months ended September 29, 2013, as compared to $0.4 million for the nine months ended September 30, 2012. Stock-based compensation expense increased and was $0.6 million for the nine months ended September 29, 2013, as compared to $0.5 million for the nine months ended September 30, 2012. Acquisition related costs related to certain acquisitions were $0.2 million for the three months ended September 29, 2013.

Restructuring and Contract Termination Charges, Net We have undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, alignment with our growth strategy and the integration of our business units. The current portion of restructuring and contract termination charges, is recorded in accrued restructuring and contract termination charges, and the long-term portion of restructuring and contract termination charges, is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, and are included as a component of operating expenses from continuing operations.
A description of the restructuring plans and the activity recorded for the nine months ended September 29, 2013 is listed below. Details of the plans initiated in previous years, particularly those listed under "Previous Restructuring and Integration Plans," are discussed more fully in Note 4 to the audited consolidated financial statements in the 2012 Form 10-K.
The restructuring plan for the third quarter of fiscal year 2013 was principally intended to shift certain of our research and development resources into a newly opened Center for Innovation. The restructuring plan for the second quarter of fiscal year 2013 was principally intended to shift certain of our operations into a newly established shared service center as well as realign operations, research and development resources and production resources as a result of previous acquisitions. The restructuring plan for the first quarter of fiscal year 2013 was principally intended to focus resources on higher growth end markets. The restructuring plan for the fourth quarter of fiscal year 2012 was principally intended to shift resources to higher growth geographic regions and end markets. The restructuring plan for the third quarter of fiscal year 2012 was principally intended to shift certain of our operations into a newly established shared service center. The restructuring plans for the first and second quarters of fiscal year 2012 were principally intended to realign operations, research and development resources and production resources as a result of previous acquisitions. We expect the impact of future cost savings on operating results and cash flows from restructuring activities executed in fiscal year 2013 will exceed $3.0 million, on an annual basis, beginning in fiscal year 2015. We expect the impact of future cost savings on operating results and cash flows from restructuring activities executed in fiscal year 2012 will exceed $11.0 million, on an annual basis, beginning in fiscal year 2014. These future cost savings will be primarily a decrease to cost of revenue and a decrease to selling, general and administrative expenses.


Table of Contents

Q3 2013 Restructuring Plan
During the third quarter of fiscal year 2013, our management approved a plan to shift certain of our research and development resources into a newly opened Center for Innovation (the "Q3 2013 Plan"). As a result of the Q3 2013 Plan, we recognized a $0.5 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. As part of the Q3 2013 Plan, we will reduce headcount by 30 employees. All employees were notified of termination under the Q3 2013 Plan by September 29, 2013.

The following table summarizes the Q3 2013 Plan activity for the nine months ended September 29, 2013:

                                                                Closure of
                                                              Excess Facility
                                               Severance           Space          Total
                                                            (In thousands)
Provision                                     $       394    $         138       $ 532
Amounts paid and foreign currency translation           -              (26 )       (26 )
Balance at September 29, 2013                 $       394    $         112       $ 506

We anticipate that the remaining severance payments of $0.4 million for workforce reductions will be substantially completed by the end of the second quarter of fiscal year 2014. We also anticipate that the remaining payments of $0.1 million for the closure of the excess facility space will be paid through fiscal year 2013, in accordance with the terms of the applicable lease.

Q2 2013 Restructuring Plan
During the second quarter of fiscal year 2013, our management approved a plan to shift certain of our operations into a newly established shared service center as well as realign operations, research and development resources, and production resources as a result of previous acquisitions (the "Q2 2013 Plan"). As a result of the Q2 2013 Plan, and during the nine months ended September 29, 2013, we recognized a $10.3 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space and recognized a $8.8 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. We expect to recognize an additional $0.3 million of incremental restructuring expense in future periods as services are provided for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits. This expense will be recognized ratably over the required service period. As part of the Q2 2013 Plan, we will reduce headcount by 265 employees. All employees were notified of termination under the Q2 2013 Plan by June 30, 2013.

The following table summarizes the Q2 2013 Plan activity for the nine months ended September 29, 2013:

                                                               Closure of
                                                             Excess Facility
                                               Severance          Space           Total
                                                             (In thousands)
Provision                                     $  18,476     $         572       $ 19,048
Amounts paid and foreign currency translation    (3,824 )            (519 )       (4,343 )
Balance at September 29, 2013                 $  14,652     $          53       $ 14,705

We anticipate that the remaining severance payments of $14.7 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014. We also anticipate that the remaining payments of $0.1 million for the closure of the facility space will be paid through fiscal year 2013, in accordance with the terms of the applicable leases.

Q1 2013 Restructuring Plan
During the first quarter of fiscal year 2013, our management approved a plan to focus resources on higher growth end markets (the "Q1 2013 Plan"). As a result of the Q1 2013 Plan, we recognized a $2.3 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q1 2013 Plan, we reduced headcount by 62 employees. All employees were notified of termination under the Q1 2013 Plan by March 31, 2013.


Table of Contents

The following table summarizes the Q1 2013 Plan activity for the nine months ended September 29, 2013:

                                                 Severance
                                               (In thousands)
Provision                                     $        2,585
Amounts paid and foreign currency translation         (2,371 )
Balance at September 29, 2013                 $          214

We anticipate that the remaining severance payments of $0.2 million for . . .

  Add PKI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for PKI - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.